CDC Issues Risk-Based Guidance on RSV Vaccines for Adults 60 and Older

The CDC updated its guidance on RSV vaccination for older adults. The agency moved from a shared clinical decision making model for all adults 60 and older to defined criteria based on age and specific health risks. This shift draws on clinical trial data and safety monitoring that followed the initial FDA approvals in 2023. The revised approach directs greater focus toward groups that have shown the highest rates of RSV related hospitalizations.

The MMWR report found that all adults 75 years and older qualify for one dose. Adults 60 to 74 years qualify if they have conditions that raise their odds of severe illness. Those conditions include heart disease, lung disease, diabetes, and weakened immunity. [1]

The report found that a single dose is administered in the fall before RSV season. [1] Three vaccines hold approval for this group. They are Arexvy from GSK, Abrysvo from Pfizer, and mResvia from Moderna. [2][3]

The update differs from the 2023 guidance. Officials initially advised shared clinical decision making for every adult 60 and older. Surveillance data that accumulated afterward let experts identify groups with the highest rates of serious outcomes and sharpen the criteria. [1]

Clinical trials measured vaccine efficacy against RSV associated lower respiratory tract disease. Post licensure safety reviews supported those findings. Benefits appeared strongest among the oldest adults and those with chronic conditions. [1]

What this means

The updated rules supply clinicians and patients with more defined criteria for discussions. Communities that include many adults 75 and older or elevated levels of chronic illness may see changes in vaccine uptake within those groups. Real world surveillance since the 2023 approvals informed the revision and clarified which populations drive most RSV hospitalizations.

Key takeaways

• All adults 75 years and older qualify for one RSV vaccine dose under the August 2023 guidance. [1]
• Adults 60 to 74 years qualify if they have underlying conditions such as heart disease, lung disease, or diabetes. [1]
• Arexvy, Abrysvo, and mResvia received FDA approval and align with current CDC recommendations for this population. [2][3]
• Clinical trials found strong efficacy against RSV related lower respiratory tract disease in adults 60 and older. [1]
• Post approval safety reviews show that benefits outweigh rare risks including Guillain Barré syndrome. [1]

Limitations

Longer term duration of protection beyond one RSV season remains uncertain. Data on vaccine effectiveness in severely immunocompromised older adults or nursing home residents are still limited. Recommendations may be refined as additional seasons of effectiveness and safety data accrue.

FAQ

Which specific age and risk groups qualify for routine RSV vaccination per the CDC update?
All adults 75 years and older qualify. Adults 60 to 74 years qualify if they have medical conditions linked to higher risk of severe RSV disease. [1]

What RSV vaccines are approved and recommended for adults aged 60 and older?
The three approved vaccines are Arexvy (GSK), Abrysvo (Pfizer), and mResvia (Moderna). [2][3]

How does the current recommendation differ from the 2023 shared clinical decision making approach?
The 2023 approach invited shared decisions for all adults 60 and older. The update replaces that with defined age and risk criteria to direct vaccination more precisely. [1]

What safety and effectiveness data support the updated recommendations?
Support comes from clinical trial results on efficacy against lower respiratory tract disease plus safety data gathered after the vaccines entered use. [1]

Sources / References

[1] Use of Respiratory Syncytial Virus Vaccines Among Older Adults, United States, 2023. https://www.cdc.gov/mmwr/volumes/72/wr/mm7232a3.htm

[2] FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine. https://www.fda.gov/news-events/press-announcements/fda-approves-first-respiratory-syncytial-virus-rsv-vaccine

[3] RSV Vaccination for Older Adults. https://www.cdc.gov/vaccines/vpd/rsv/hcp/older-adults.html